Analyst Price Target is $40.00
▲ +451.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pasithea Therapeutics in the last 3 months. The average price target is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The average price target represents a 451.70% upside from the last price of $7.25.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Pasithea Therapeutics. This Buy consensus rating has held steady for over two years.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Read More